Day: April 8, 2022

— CB-011 is an allogeneic anti-BCMA CAR-T cell therapy immune cloaked to blunt both T- and NK-mediated immune cell rejection, enabling more durable antitumor activity — — Data support an expected Investigational New Drug (IND) application submission in 2022 for CB-011, Caribou’s second allogeneic cell therapy product candidate — BERKELEY, Calif., April 08, 2022 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the presentation of positive preclinical data for its allogeneic, immune-cloaked, anti-BCMA CAR-T cell therapy candidate, CB-011, being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM). The data are being presented at the American Association for Cancer Research (AACR)...

Preclinical data featured in three posters show potential of KB-0742 in triple-negative breast, lung and ovarian cancers, as well as lymphoma and rare, soft-tissue cancers, including sarcoma and chordoma Company will also present data demonstrating the potential of its new liquid biopsy assay platform to help evaluate patient response to KB-0742 in the ongoing Phase 1/2 study Kronos Bio continues to enroll patients in Phase 1/2 clinical trial, with additional data anticipated in Q4 2022 SAN MATEO, Calif. and CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today shared preclinical data on its internally discovered, highly selective, oral cyclin dependent kinase 9 (CDK9) inhibitor, KB-0742, adding...

VIP152 demonstrates antitumor responses in preclinical models of gynecologic malignancies Preliminary monotherapy clinical results presented for VIP152-treated patients with gynecologic cancers PALO ALTO, Calif., April 08, 2022 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced a poster presentation of preclinical and preliminary clinical data on VIP152, the Company’s PTEFb/CDK9 inhibitor, in gynecologic cancer cell lines and in patients with gynecologic malignancies, respectively, at the 2022 American Association for Cancer Research (AACR) Annual Meeting, being held virtually and in New Orleans, Louisiana from April 8-13, 2022. “The preclinical data presented at AACR demonstrate...

– Data highlight PYX-106’s differentiated activity profile and antitumor activity in an in vivo mouse model – – Preclinical data support IND filing in 2H 2022 – CAMBRIDGE, Mass. and NEWARK, Del. and NANJING, China, April 08, 2022 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS) today announced preclinical data supporting the potential of anti-Siglec-15 BSI-060T (now PYX-106) presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting, taking place in New Orleans, Louisiana, April 8-13, 2022. “While immunotherapies hold immense potential to improve the lives of patients with cancer, current therapeutics have demonstrated success in only a narrow range of tumor types,” said Ronald Herbst, Ph.D., Chief Scientific Officer of Pyxis Oncology. “We believe that the...

BOSTON, April 08, 2022 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, today announced that it will present a poster on its Waldenström’s macroglobulinemia program at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022 to be held in New Orleans, LA April 8-12, 2022. Presentation Details: Poster Title: Mavorixafor Enhances Efficacy of Bruton’s Tyrosine Kinase Inhibitors by Overcoming the Protective Effect of Bone Marrow Stroma on Tumor Cells in Waldenström’s Macroglobulinemia Presenter: Chi Nguyen Ph.D., Group Leader, Discovery at X4 PharmaceuticalsPoster #: 6093   Poster Session: Drug Targeting and Treatment Response of the MicroenvironmentSession...

    GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with advanced solid tumors and progressive disease Dose escalation continues toward potentially more effective regimen Initial translational data corroborate clinical findings PLANETTM manufacturing process is highly reliable and continues to improve; patients next to be dosed to receive GEN-011 with substantially boosted yields, neoantigen specificity and potency Investor webcast at 4:30 pm ET today to further discuss data CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, presents clinical, preclinical, and manufacturing data at the American Association for Cancer Research (AACR) Annual...

MDM2 degradation demonstrated differentiated biological activity and superior cell killing compared to small molecule inhibition in p53 wild-type tumors and led to tumor regressions in xenograft models of ALL and AML KT-253 is a highly potent and selective heterobifunctional MDM2 degrader whose mechanism of action overcomes the MDM2-p53 autoregulatory feedback loop that limits the activity of MDM2 small molecule inhibitors WATERTOWN, Mass., April 08, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today presented preclinical data from its 4th development program, a novel MDM2 degrader, at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place...

Studies provide insight into bifunctional molecular mechanism and first in vivo demonstration of immunomodulatory imide drug (IMiD) activity of NX-2127, resulting in robust tumor cell killing Animal models of adoptive cell therapy support the use of NX-0255 in the production of an investigational drug-enhanced TIL therapy, DeTIL-0255 SAN FRANCISCO, April 08, 2022 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced the presentation of preclinical data that support the clinical development of investigative therapies NX-2127 and DeTIL-0255, for the treatment of B-cell malignancies and solid tumors, respectively, at the American Association for Cancer Research (AACR) Annual Meeting. The meeting is being held from April...

CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) — Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the presentation of biomarker signature data from two studies evaluating vidutolimod, a first-in-class, immunostimulatory, noninfectious virus-like particle (VLP) containing a CpG-A Toll-like receptor 9 (TLR9) agonist. The first study evaluated vidutolimod in patients with advanced anti-PD-(L)1 refractory melanoma who received intratumoral vidutolimod monotherapy or in combination with intravenous pembrolizumab, and the second evaluated patients with anti-PD-(L)1 refractory non-small cell lung cancer (NSCLC) who received vidutolimod and atezolizumab. The...

BOSTON, April 08, 2022 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage oncology focused biotechnology company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported new preclinical data on CTX-8371, a next generation bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1 and exhibits a unique MOA that involves cleavage of cell surface PD-1, at the American Association for Cancer Research (AACR) Annual Meeting, which is being held April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana (Abstract Number: 5027; Session Title: Combination Immunotherapies / Therapeutic Antibodies). Key data presented includes the following:Treatment with CTX-8371 leads to PD-1 loss from the surface of intra-tumoral T cells...